One of the best and longest-studied defense response of plants to infection is the induced accumulation of antimicrobial, low-molecular-weight secondary metabolites known as phytoalexins. Since the phytoalexin hypothesis was first proposed in 1940, a role for these compounds in defense has been revealed through several experimental approaches. Support has come, for example, through studies on the rate of phytoalexins in relation to cessation of pathogen development, quantification of phytoalexins at the infection site, and relationship of pathogen virulence to the phytoalexin tolerance. Evidence in support of phytoalexins in resistance as well some recent advances in phytoalexin biosynthesis are reviewed. Criteria for evaluating a role for phytoalexins in disease resistance are also discussed.
Severity of Sclerotinia stem rot of soybean after treatment with lactofen (Cobra) and other herbicides was assessed in field experiments conducted in Michigan from 1995 to 1997. At sites where disease pressure was high, disease severity was reduced 40 to 60% compared with controls when lactofen was applied at the V3 (1995 and 1996) or R1 (1997) growth stages. Corresponding seed yields were unchanged or up to 20% greater when lactofen was applied at the R1 stage in 1997. Disease severity was not reduced by lactofen treatments in years and at sites where disease pressure was low to medium, and corresponding yields often were reduced by 10%. High levels of glyceollin accumulated in lactofen-injured leaves collected from field plots in 1996 and 1997. High glyceollin content in lactofen-treated leaves was associated with significant reductions in lesion size when leaves were challenge-inoculated with Sclerotinia sclerotiorum.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.